These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26679828)

  • 41. Synergistic activity of imatinib and AR-42 against chronic myeloid leukemia cells mainly through HDAC1 inhibition.
    Wei D; Lu T; Ma D; Yu K; Zhang T; Xiong J; Wang W; Zhang Z; Fang Q; Wang J
    Life Sci; 2018 Oct; 211():224-237. PubMed ID: 30248347
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
    Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
    Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Spred2 modulates the erythroid differentiation induced by imatinib in chronic myeloid leukemia cells.
    Yang Y; Liu X; Xiao F; Xue S; Xu Q; Yin Y; Sun H; Xu J; Wang H; Zhang Q; Wang H; Wang L
    PLoS One; 2015; 10(2):e0117573. PubMed ID: 25688862
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effect of Csn-B Combined with Imatinib on Apoptosis of Chronic Myeloid Leukemia Cells through Nur77/Pim-1/Drp1 Pathway].
    Gong YX; Yang ZJ; Cao JM; Liu HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1078-1084. PubMed ID: 39192401
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EphB4-VAV1 signaling pathway is associated with imatinib resistance in chronic myeloid leukemia cells.
    Zhang JF; Xu N; Du QF; Li R; Liu XL
    Blood Cells Mol Dis; 2016 Jul; 59():58-62. PubMed ID: 27282569
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
    Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
    Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [CRISPR/Cas9-mediated microRNA-21 knockout increased imatinib sensitivity in chronic myeloid leukemia cells].
    Zhang Y; Wang LY; Li JZ; Jiang PF; Hu JD; Chen BY
    Zhonghua Xue Ye Xue Za Zhi; 2021 Mar; 42(3):243-249. PubMed ID: 33910311
    [No Abstract]   [Full Text] [Related]  

  • 49. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exosomes from mesenchymal stromal cells enhance imatinib-induced apoptosis in human leukemia cells via activation of caspase signaling pathway.
    Liu Y; Song B; Wei Y; Chen F; Chi Y; Fan H; Liu N; Li Z; Han Z; Ma F
    Cytotherapy; 2018 Feb; 20(2):181-188. PubMed ID: 29269240
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells.
    Wang J; Lu L; Kok CH; Saunders VA; Goyne JM; Dang P; Leclercq TM; Hughes TP; White DL
    Haematologica; 2017 May; 102(5):843-853. PubMed ID: 28154092
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential expression and alternative splicing of cell cycle genes in imatinib-treated K562 cells.
    Liu J; Lin J; Huang LF; Huang B; Xu YM; Li J; Wang Y; Zhang J; Yang WM; Min QH; Wang XZ
    Tumour Biol; 2015 Sep; 36(10):8127-36. PubMed ID: 25983000
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance.
    Cilloni D; Messa F; Arruga F; Defilippi I; Morotti A; Messa E; Carturan S; Giugliano E; Pautasso M; Bracco E; Rosso V; Sen A; Martinelli G; Baccarani M; Saglio G
    Leukemia; 2006 Jan; 20(1):61-7. PubMed ID: 16270044
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3.
    Wang H; Xie B; Kong Y; Tao Y; Yang G; Gao M; Xu H; Zhan F; Shi J; Zhang Y; Wu X
    Oncotarget; 2016 Apr; 7(14):18638-50. PubMed ID: 26942564
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells.
    Puissant A; Colosetti P; Robert G; Cassuto JP; Raynaud S; Auberger P
    Leukemia; 2010 Jan; 24(1):115-24. PubMed ID: 19924144
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CREB/Sp1-mediated MCL1 expression and NFκB-mediated ABCB1 expression modulate the cytotoxicity of daunorubicin in chronic myeloid leukemia cells.
    Chiou JT; Huang CH; Wu TH; Wang LJ; Lee YC; Huang PW; Chang LS
    Toxicol Appl Pharmacol; 2022 Jan; 435():115847. PubMed ID: 34963561
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells.
    Oh B; Kim TY; Min HJ; Kim M; Kang MS; Huh JY; Kim Y; Lee DS
    Anticancer Drugs; 2013 Jan; 24(1):20-31. PubMed ID: 23075630
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.
    Arunasree KM; Roy KR; Anilkumar K; Aparna A; Reddy GV; Reddanna P
    Leuk Res; 2008 Jun; 32(6):855-64. PubMed ID: 18083230
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MicroRNA-7 inhibits cell proliferation of chronic myeloid leukemia and sensitizes it to imatinib in vitro.
    Jiang MJ; Dai JJ; Gu DN; Huang Q; Tian L
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):372-378. PubMed ID: 28986256
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
    Li J; Xue L; Hao H; Han Y; Yang J; Luo J
    Oncol Rep; 2012 Feb; 27(2):461-6. PubMed ID: 21993902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.